The current valuation score of Unicycive Therapeutics Inc is 7.33, ranking 186 out of 385 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.23, which is -792.98% below the recent high of 15.42 and -118.59% above the recent low of -4.86.
P/E
Relevant data have not been disclosed by the company yet.
P/B
Relevant data have not been disclosed by the company yet.
P/S
Relevant data have not been disclosed by the company yet.
P/CF
Relevant data have not been disclosed by the company yet.